Skip to content
Comparison

Retatrutide vs Ozempic

Retatrutide and Ozempic are commonly compared for next-generation versus current standard GLP-1 care. Retatrutide is usually favored for triple-agonist upside and future efficacy ceiling, while Ozempic is often preferred for currently approved, accessible semaglutide pathway. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For next-generation versus current standard GLP-1 care, the better choice depends on your primary endpoint. Retatrutide is stronger when the priority is tracking future investigational obesity therapies. Ozempic is stronger when the priority is current real-world treatment availability. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaRetatrutideOzempic
Primary mechanismTriple agonist (GIP/GLP-1/glucagon)GLP-1 receptor agonist (semaglutide) for glycemic control
Strongest clinical signalUp to ~24% weight loss in phase 2 obesity data~1.5-2.0% A1C reduction; moderate weight loss in diabetes cohorts
Typical dosing contextInvestigational weekly titration protocols0.25 mg start, titrated to 1-2 mg weekly
AdministrationWeekly subcutaneous injectionWeekly subcutaneous injection
Evidence quality gradePromising phase 2 data; phase 3 confirmation pendingStrong for type 2 diabetes; moderate for obesity at Ozempic doses
Regulatory statusNot FDA-approved (investigational)FDA-approved for type 2 diabetes
Side-effect burdenGI effects plus active trial-stage uncertaintyGI effects common; boxed thyroid C-cell warning
Cost/access contextCommercial pricing unavailable before approvalHigh list price; insurance-dependent access
Best candidate profileFuture-oriented candidates tracking next-gen obesity therapiesT2D patients needing cardio-metabolic risk reduction
Main limitationNo approved access; long-term safety not finalizedWeight-loss ceiling lower than obesity-dose pathways
Best use case in this comparisontracking future investigational obesity therapiescurrent real-world treatment availability

When to Choose Each

Choose Retatrutide

Best for tracking future investigational obesity therapies.

Choose Ozempic

Best for current real-world treatment availability.

Verdict

If the main goal is tracking future investigational obesity therapies, Retatrutide is usually the better first-line choice. If the main goal is current real-world treatment availability, Ozempic is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial (2023) — PubMed
  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial (2023) — PubMed
  3. GIP/GLP-1/glucagon receptor co-agonism for the treatment of obesity and type 2 diabetes (2023) — PubMed
  4. Retatrutide phase 2 trial results: efficacy on liver fat reduction in participants with MASLD (2024) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for next-generation versus current standard GLP-1 care — Retatrutide or Ozempic?
Retatrutide is graded as promising phase 2 data; phase 3 confirmation pending evidence in this context, while Ozempic is graded as strong for type 2 diabetes; moderate for obesity at ozempic doses. In practice, strength depends on whether you prioritize tracking future investigational obesity therapies or current real-world treatment availability. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Retatrutide and Ozempic be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next